Starling Oncology, Inc. (STLNW) stock
STLNWNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLN
$0.03+0.00 (+10.87%)
Close on Oct 30, 2026Market cap $665.51MP/E –Yield –
Starling Oncology operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Starling Oncology's operating income for the twelve months ending Jun 30, 2026 was -$26.09M. For fiscal 2025 it was -$36.08M. The highest annual figure on record is -$8.20M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$36.08M | – |
| FY2024 | Dec 31, 2024 | -$60.12M | – |
| FY2023 | Dec 31, 2023 | -$77.02M | – |
| FY2022 | Dec 31, 2022 | -$81.95M | – |
| FY2021 | Dec 31, 2021 | -$45.86M | – |
| FY2020 | Dec 31, 2020 | -$8.20M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.62M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.51M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.91M | – |
| Q3 FY2025 | Sep 30, 2025 | -$8.05M | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.21M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.91M | – |
| Q4 FY2024 | Dec 31, 2024 | -$11.93M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.85M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.36M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.97M | – |
| Q4 FY2023 | Dec 31, 2023 | -$15.29M | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.93M | – |
| Q2 FY2023 | Jun 30, 2023 | -$14.94M | – |
| Q1 FY2023 | Mar 31, 2023 | -$32.87M | – |
| Q4 FY2022 | Dec 31, 2022 | -$25.08M | – |
| Q3 FY2022 | Sep 30, 2022 | -$20.10M | – |
| Q2 FY2022 | Jun 30, 2022 | -$18.30M | – |
| Q1 FY2022 | Mar 31, 2022 | -$18.47M | – |
| Q4 FY2021 | Dec 31, 2021 | -$40.83M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.16M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.12M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.75M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.72M | – |
| Q3 FY2020 | Sep 30, 2020 | -$198.48K | – |
| Q2 FY2020 | Jun 30, 2020 | -$194.56K | – |
| Q1 FY2020 | Mar 31, 2020 | -$87.77K | – |